AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.12.22	AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline (PR Newswire)
06.12.22	AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress (PR Newswire)
01.12.22	AbbVie Announces Provincial Reimbursement For RINVOQ For Rheumatoid Treatment (RTTNews)
29.11.22	Starkes Investment in US-Aktien: Diese Titel hielt die UBS im dritten Quartal (finanzen.ch) Im Rahmen des 13F-Formulars legte die Schweizer Grossbank UBS kürzlich ihre Beteiligungen an US-Aktien vor. Diese Werte machen den grössten Anteil im US-Depot der Zürcher aus.» mehr
23.11.22	AbbVie to Present at the Evercore ISI HealthCONx Conference (PR Newswire)
23.11.22	AbbVie: SKYRIZI (risankizumab) Gets EU Approval To Treat Moderate To Severe Active Crohn's Disease (RTTNews)
23.11.22	AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease (PR Newswire)
22.11.22	AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting (PR Newswire)
22.11.22	AbbVie to Present at the Piper Sandler Healthcare Conference (PR Newswire)
21.11.22	AbbVie: FDA To Review BLA For Epcoritamab - Quick Facts (RTTNews)
21.11.22	U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (PR Newswire)
17.11.22	Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet (PR Newswire)
09.11.22	AbbVie to Present at the Wolfe Research Healthcare Conference (PR Newswire)
08.11.22	AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022 (PR Newswire)
08.11.22	AbbVie : Phase 2 Trial Of AGN-151607 In POAF In Cardiac Surgery Patients Fails To Meet Main Goal (RTTNews)
07.11.22	AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery... (PR Newswire)
03.11.22	Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness (PR Newswire)
02.11.22	Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day (PR Newswire)
28.10.22	AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relapsed/refractory Diffuse Large B-cell (RTTNews)
28.10.22	AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma... (PR Newswire)
28.10.22	AbbVie Q3 Profit Increases, beats estimates (RTTNews)
28.10.22	AbbVie Reports Third-Quarter 2022 Financial Results (PR Newswire)
28.10.22	MARKT USA/Leichter erwartet - Techwerte erneut unter Druck (Dow Jones)
27.10.22	Ausblick: AbbVie zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
24.10.22	AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting (PR Newswire)
21.10.22	FDA Approves AbbVie's Rinvoq For Treatment Of Active Non-radiographic Axial Spondyloarthritis (RTTNews)
21.10.22	RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval (PR Newswire)
20.10.22	AbbVie To Buy UK-based Biotechnology Company DJS Antibodies For About $255 Mln (RTTNews)
20.10.22	AbbVie: SKYRIZI Gets Health Canada Approval To Treat Moderately To Severely Active Crohn's Disease (RTTNews)
20.10.22	AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline (PR Newswire)
17.10.22	AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire (PR Newswire)
13.10.22	Erste Schätzungen: AbbVie präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
07.10.22	Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting (PR Newswire)
04.10.22	AbbVie to Host Third-Quarter 2022 Earnings Conference Call (PR Newswire)
29.09.22	AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022 (PR Newswire)
22.09.22	The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery (PR Newswire)
19.09.22	AbbVie Receives CHMP Positive Opinion For Skyrizi For Moderate To Severe Crohn's Disease (RTTNews)
19.09.22	AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease (PR Newswire)
15.09.22	AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress (PR Newswire)
14.09.22	AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards" (PR Newswire)
13.09.22	Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories (PR Newswire)
10.09.22	New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 (PR Newswire)
09.09.22	AbbVie Declares Quarterly Dividend (PR Newswire)
08.09.22	New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients (PR Newswire)
08.09.22	AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022 (PR Newswire)
07.09.22	Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM® (PR Newswire)
07.09.22	AbbVie to Present at the Morgan Stanley Healthcare Conference (PR Newswire)
31.08.22	SkinMedica® Launches Firm & Tone Lotion for Body (PR Newswire)
30.08.22	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report (PR Newswire)
29.08.22	AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten